AU2015266053B2 - Combination comprising a glucocorticoid and EDO-S101 - Google Patents

Combination comprising a glucocorticoid and EDO-S101 Download PDF

Info

Publication number
AU2015266053B2
AU2015266053B2 AU2015266053A AU2015266053A AU2015266053B2 AU 2015266053 B2 AU2015266053 B2 AU 2015266053B2 AU 2015266053 A AU2015266053 A AU 2015266053A AU 2015266053 A AU2015266053 A AU 2015266053A AU 2015266053 B2 AU2015266053 B2 AU 2015266053B2
Authority
AU
Australia
Prior art keywords
cancer
combination
glucocorticoid
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015266053A
Other languages
English (en)
Other versions
AU2015266053A1 (en
Inventor
Thomas Jorg MEHRLING
Enrique Maria OCIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of AU2015266053A1 publication Critical patent/AU2015266053A1/en
Application granted granted Critical
Publication of AU2015266053B2 publication Critical patent/AU2015266053B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2015266053A 2014-05-28 2015-05-26 Combination comprising a glucocorticoid and EDO-S101 Active AU2015266053B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1409485.8A GB201409485D0 (en) 2014-05-28 2014-05-28 Pharmaceutical composition
GB1409485.8 2014-05-28
PCT/EP2015/061572 WO2015181157A1 (en) 2014-05-28 2015-05-26 Combination comprising a glucocorticoid and edo-s101

Publications (2)

Publication Number Publication Date
AU2015266053A1 AU2015266053A1 (en) 2016-11-17
AU2015266053B2 true AU2015266053B2 (en) 2020-07-02

Family

ID=51177587

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015266053A Active AU2015266053B2 (en) 2014-05-28 2015-05-26 Combination comprising a glucocorticoid and EDO-S101

Country Status (19)

Country Link
US (4) US10744120B2 (enExample)
EP (1) EP3148584B1 (enExample)
JP (2) JP2017518292A (enExample)
KR (1) KR20170008846A (enExample)
CN (1) CN106488776B (enExample)
AU (1) AU2015266053B2 (enExample)
BR (1) BR112016027043B1 (enExample)
CA (1) CA2950340C (enExample)
DK (1) DK3148584T3 (enExample)
EA (1) EA038323B1 (enExample)
ES (1) ES2885429T3 (enExample)
GB (1) GB201409485D0 (enExample)
IL (1) IL249230A0 (enExample)
MX (1) MX383254B (enExample)
PH (1) PH12016502352A1 (enExample)
SG (2) SG10201810404XA (enExample)
TW (1) TWI731837B (enExample)
UA (1) UA121392C2 (enExample)
WO (1) WO2015181157A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2018068832A1 (en) * 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
EP3897626B1 (en) * 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040286A2 (en) * 2011-09-18 2013-03-21 Euro-Celtique S.A. Pharmaceutical compositions
WO2013113838A1 (en) * 2012-02-01 2013-08-08 Euro-Celtique Novel therapeutic agents

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6133248A (en) 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
AU2001273413A1 (en) 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7569724B2 (en) 2000-09-29 2009-08-04 Topotarget Uk Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
CN1764648A (zh) 2003-01-13 2006-04-26 安斯泰来制药有限公司 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
AU2004215624B2 (en) 2003-02-25 2011-06-02 Topotarget Uk Limited Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
WO2005013958A1 (en) 2003-08-07 2005-02-17 Novartis Ag Histone deacetylase inhibitors as immunosuppressants
WO2005097747A1 (en) 2004-04-05 2005-10-20 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CA2606598C (en) 2005-05-13 2014-12-23 Topotarget Uk Limited Pharmaceutical formulations of hdac inhibitors
EA200900571A1 (ru) 2006-10-20 2009-12-30 Айкос Корпорейшн Композиции chk1 ингибиторов
GB0621160D0 (en) 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
WO2008063644A1 (en) 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
CN101084876A (zh) 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009067453A1 (en) 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
EP2889029A1 (en) 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
CN102177140B (zh) 2008-10-08 2016-01-27 赛福伦公司 用于制备苯达莫司汀的方法
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
ME02254B (me) 2009-01-23 2015-12-31 Euro Celtique Sa Derivati hidroksamske kiseline
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011017448A1 (en) 2009-08-05 2011-02-10 The Trustees Of The University Of Pennsylvania Use of histone deacetylase inhibitors for treatment of autoimmune diseases
CN101928234B (zh) 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
ES2605586T3 (es) 2010-04-16 2017-03-15 Cellact Pharma Gmbh Análogos de etopósido para el tratamiento de tumores metastásicos
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US8748470B2 (en) 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
CN102993102B (zh) 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法
AU2012316084B2 (en) 2011-09-28 2016-10-27 Euro-Celtique S.A. Nitrogen mustard derivatives
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
NZ630314A (en) 2014-02-18 2016-03-31 Celgene Corp Combination therapy for hematological malignancies
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
AU2015356779A1 (en) 2014-12-05 2017-07-13 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
US20180311215A1 (en) 2015-10-20 2018-11-01 Hangzhou TINO Pharma Co., Ltd. Pharmaceutical composition and preparation method therefor
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
US20180098969A1 (en) 2016-10-11 2018-04-12 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
EP3897626B1 (en) 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040286A2 (en) * 2011-09-18 2013-03-21 Euro-Celtique S.A. Pharmaceutical compositions
WO2013113838A1 (en) * 2012-02-01 2013-08-08 Euro-Celtique Novel therapeutic agents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEN LI-PING ET AL, ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI SEP 2013, (2013-09), vol. 34, no. 9, ISSN 0253-2727, pages 741 - 744 *
ENRIQUE M OCIO ET AL, BLOOD, US, (2007-11-16), vol. 110, no. 11, Part 1, ISSN 0006-4971 *
HARRISON S J ET AL, BLOOD; ASH ANNUAL MEETING ABSTRACTS, AMERICAN SOCIETY OF HEMATOLOGY, US, (2008-01-01), ISSN 0006-4971, pages 1 - 2 *
JONATHAN L KAUFMAN ET AL, BLOOD, US, (2012-11-16), vol. 120, no. 21, ISSN 0006-4971, page 336 *
P. S. BACHMANN ET AL, BLOOD, (2010-07-20), vol. 116, no. 16, doi:10.1182/blood-2010-05-284968, ISSN 0006-4971, pages 3013 - 3022 *
PHILIPPE MOREAU ET AL, BLOOD, US, (2013-11-15), vol. 122, no. 21, ISSN 0006-4971 *

Also Published As

Publication number Publication date
JP2021046446A (ja) 2021-03-25
ES2885429T3 (es) 2021-12-13
GB201409485D0 (en) 2014-07-09
US10744120B2 (en) 2020-08-18
BR112016027043A2 (pt) 2017-08-15
SG11201609362YA (en) 2016-12-29
EP3148584B1 (en) 2021-05-26
US20170296513A1 (en) 2017-10-19
US20210059989A1 (en) 2021-03-04
US12064417B2 (en) 2024-08-20
EA038323B1 (ru) 2021-08-10
US11541038B2 (en) 2023-01-03
JP2017518292A (ja) 2017-07-06
MX2016015437A (es) 2017-06-23
TW201613577A (en) 2016-04-16
US20230285363A1 (en) 2023-09-14
KR20170008846A (ko) 2017-01-24
SG10201810404XA (en) 2018-12-28
US20250049762A1 (en) 2025-02-13
UA121392C2 (uk) 2020-05-25
MX383254B (es) 2025-03-13
EP3148584A1 (en) 2017-04-05
EA201692481A1 (ru) 2017-04-28
TWI731837B (zh) 2021-07-01
AU2015266053A1 (en) 2016-11-17
CN106488776B (zh) 2021-01-22
DK3148584T3 (da) 2021-08-30
CA2950340A1 (en) 2015-12-03
IL249230A0 (en) 2017-02-28
WO2015181157A1 (en) 2015-12-03
BR112016027043A8 (pt) 2021-07-20
PH12016502352A1 (en) 2017-02-13
CN106488776A (zh) 2017-03-08
CA2950340C (en) 2023-10-17
BR112016027043B1 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
US12403130B2 (en) Pharmaceutical combinations for treating cancer
US12064417B2 (en) Combination comprising a glucocorticoid and EDO-S101
US9993482B2 (en) Pharmaceutical combination comprising a class III receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule EDO-S101 together with its use in the treatment of cancer
HK1235679B (en) Combination comprising a glucocorticoid and edo-s101

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)